Alpha 2.0
Login Register
» Articles » PMID: 34590138

Hepatitis B Vaccines

Overview
Journal J Infect Dis
Publisher Oxford University Press
Specialty Infectious Diseases
Date 2021 Sep 30
PMID 34590138
Citations 86
Authors
Jade Pattyn
Greet Hendrickx
Alex Vorsters
Pierre Van Damme
Affiliations
Soon will be listed here.
Abstract

Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality. Affordable, safe, and effective, hepatitis B vaccines are the best tools we have to control and prevent hepatitis B. In 2019, coverage of 3 doses of the hepatitis B vaccine reached 85% worldwide compared to around 30% in 2000. The effective implementation of hepatitis B vaccination programs has resulted in a substantial decrease in the HBV carrier rate and hepatitis B-related morbidity and mortality. This article summarizes the great triumphs of the hepatitis B vaccine, the first anticancer and virus-like-particle-based vaccine. In addition, existing unresolved issues and future perspectives on hepatitis B vaccination required for global prevention of HBV infection are discussed.

Citing Articles

Antenatal Screening for Hepatitis B Virus in Uganda: Missed Opportunities for Diagnosis and Treatment.

Etti M, Davies H, Amone A, Kyohere M, Tusubira V, Burt J Open Forum Infect Dis. 2025; 11(Suppl 3):S193-S199.

PMID: 40070700 PMC: 11891135. DOI: 10.1093/ofid/ofae603.

The interplay of socio-demographic factors and disease prevalence: insights into malaria, Hepatitis B, and Hepatitis C in Lafia, Nasarawa State, Nigeria.

Aremu D, Maxim A, Aremu S, Aremu D, Terhemen Y, Itodo S J Health Popul Nutr. 2025; 44(1):67.

PMID: 40051006 PMC: 11883923. DOI: 10.1186/s41043-025-00779-5.

Vertical transmission of hepatitis B virus in the WHO African region: a systematic review and meta-analysis.

Riches N, Henrion M, MacPherson P, Hahn C, Kachala R, Mitchell T Lancet Glob Health. 2025; 13(3):e447-e458.

PMID: 40021303 PMC: 11868780. DOI: 10.1016/S2214-109X(24)00506-0.

Prevalence of hepatitis B virus infection and treatment eligibility in Lesotho, Southern Africa: a population-based cross-sectional study with case-based follow-up.

Firima E, Ntsoaki R, Lukau B, Tlahali M, Gonzalez Fernandez L, Manthabiseng M BMJ Public Health. 2025; 2(2):e001195.

PMID: 40018538 PMC: 11816210. DOI: 10.1136/bmjph-2024-001195.

Immunosuppressive Treatments and Risk Factors Associated with Non-Response to Hepatitis B Vaccination: A Cohort Study.

Padilla-Matas R, Salguero-Cano V, Soler-Iborte E, Baca-Hidalgo J, Perez-Dionisio M, Gutierrez-Linares S Vaccines (Basel). 2025; 13(2).

PMID: 40006731 PMC: 11861145. DOI: 10.3390/vaccines13020184.

References
1.
Blumberg B, Alter H, VISNICH S . A "NEW" ANTIGEN IN LEUKEMIA SERA. JAMA. 1965; 191:541-6. DOI: 10.1001/jama.1965.03080070025007. View
2.
Beutels P . Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ. 2001; 10(8):751-74. DOI: 10.1002/hec.625. View
3.
Edmunds W, Medley G, Nokes D, Hall A, Whittle H . The influence of age on the development of the hepatitis B carrier state. Proc Biol Sci. 1993; 253(1337):197-201. DOI: 10.1098/rspb.1993.0102. View
4.
Leuridan E, Van Damme P . Hepatitis B and the need for a booster dose. Clin Infect Dis. 2011; 53(1):68-75. DOI: 10.1093/cid/cir270. View
5.
Kane M . Global status of hepatitis B immunisation. Lancet. 1996; 348(9029):696. DOI: 10.1016/S0140-6736(05)65598-5. View